Join our community of smart investors

Steady progress at Reckitt

RESULTS: Restructuring to focus on faster-growth areas appears to be paying off for Reckitt Benckiser
February 13, 2013

Reckitt Benckiser (RB.) has been restructuring in order to focus on faster-growing emerging markets and health and hygiene products, while also cutting costs. Despite tough market conditions, that's paying off and full-year like-for-like sales growth reached 5 per cent (at constant currencies), while the gross margin improved 50 basis points to 57.9 per cent.

IC TIP: Hold at 4,404p

The Latin America and Asia division reported a 17 per cent jump in underlying profits to £464m - driven by sales of brands such as Durex and Scholl. Underlying profits rose 3 per cent to £290m at the Russia, Middle East and Africa operations, despite competitive markets. The newly created Europe North America unit made progress, too, with sales there up 3 per cent in the fourth quarter - helped by demand for such products as Strepsils amid a higher incidence of cold and flu.

Reckitt entered the fast-growing vitamins market in December, too, after acquiring Schiff for $1.4bn (£892m). It also announced a three-year agreement this month with Bristol-Myers Squibb to sell its healthcare brands in Brazil and Mexico. And, while pharmaceuticals - responsible for a fifth of earnings - faces generic competition for opiate dependency product, suboxone, the development of a film-based delivery system offers some defence.

Deutsche Bank expects 2013 adjusted EPS of 269.5p (from 264.4p in 2012).

RECKITT BENCKISER (RB.)
ORD PRICE:4,404pMARKET VALUE:£31.7bn
TOUCH:4,403-4,404p12-MONTH HIGH:4,498pLOW: 3,274p
DIVIDEND YIELD:3.0%PE RATIO:17
NET ASSET VALUE:823p*NET DEBT:41%

Year to 31 DecTurnover (£bn)Pre-tax profit (£bn)Earnings per share (p)Dividend per share (p)
20086.561.4715880.0
20097.751.89199100
20108.452.14217115
20119.492.38240125
20129.572.42253134
% change+1+2+5+7

Ex-div: 20 Feb

Payment: 30 May

*Includes intangible assets of £11.2bn, or 1,554p a share